18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study

Conclusion: 18F-rhPSMA-7 PET/CT demonstrates high detection rates in prostate cancer patients with BCR after primary radiation therapy, even at low PSA values. Its diagnostic efficacy is comparable to published data for other PSMA ligands.

Source: Journal of Nuclear Medicine - August 1, 2022 Category: Nuclear Medicine Authors: Ilhan, H., Kroenke, M., Wurzer, A., Unterrainer, M., Heck, M., Belka, C., Knorr, K., Langbein, T., Rauscher, I., Schmidt-Hegemann, N.-S., Schiller, K., Bartenstein, P., Wester, H.-J., Eiber, M. Tags: Clinical Investigations Source Type: research